2025-522921-37-00CompletedPhase 1
An open-label, randomized, single-dose, two-period, two-treatment, crossover bioequivalence study with GP-IMP-001 in healthy male volunteers under fasting conditions.
Source: EU CTIS (euclinicaltrials.eu) · Last updated 11 Sept 2025
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 36 (actual)
- First submitted
- 25 Aug 2025
- Start date
- 22 Oct 2025
- Lead sponsor
- Gebro Pharma GmbH
- EU CT number
- 2025-522921-37-00
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 36
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Cepha s.r.o. | Plzen 1 | Czechia | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.